Tumors can use an enzyme called ART1 to thwart antitumor immune cells, making the enzyme a promising new target for immunity-boosting cancer treatments, according to a study from researchers at Weill Cornell Medicine and Albert Einstein College of Medicine.
Meiogenix, a next-generation technology startup that helps agricultural crops find their own genetic solutions, via chromosome editing, has joined Cornell’s McGovern Center incubator.
Most patients with severe COVID who are put on ventilators regain consciousness after removal of respiratory support, but recovery may take weeks after the period of mechanical ventilation has ended, according to a new study.
A Cornell startup is working with the Performance Apparel Design Lab to take its wearable sensor technology, which can track the movement of athletes, and use it to monitor pilots undergoing high-gravitational-force training.
Students are invited to enroll now for Cornell’s Summer Session where they can earn up to 15 credits. Courses are offered online, on campus and around the world in three-, six- and eight-week sessions between May 31 and August 2, 2022.
New research from Manoj Thomas, marketing professor at Johnson, and Shreyans Goenka, Ph.D. ’20, finds that low-income conservatives are just as likely as liberals to accept federal assistance, so long as there’s a work requirement.
A new Cornell study sheds light on a controversial debate in epigenetics – the set of molecular changes occurring on top of the genome that regulate how genes are turned on and off, but without changing a cell’s DNA sequence.
Anti-Mullerian hormone, traditionally thought of as a passive byproduct of polycystic ovary syndrome, may actually play an active role in the disorder, according to new research.
Globally, by the end of this century low-income cattle farmers in poor countries may face financial loss between $15 to $40 billion annually, due to looming climate change.
